Subsequent experimental validation confirmed the overexpression of KRT6B in LUAD tumor cells and demonstrated its tumor-promoting functions both <i>in vitro</i> and <i>in vivo</i>.<h4>Conclusion</h4>We established and validated an immune-related gene signature for prognostic prediction and identified KRT6B as a promising prognostic biomarker and potential therapeutic target in LUAD. The gene discussed is KRT6B; the disease is neoplasm.